IP Library › Granted Patent US 11,052,152
Granted Patent B2
US 11,052,152 · App. 17/030,325 · Granted Jul 6, 2021

Transdermal carrier

Inventors: Bruce J. Sand (Westlake Village, CA); Ryan R. Beal (Thousand Oaks, CA); Philippe H. Burnham (Thousand Oaks, CA)
Assignee: DYVE BIOSCIENCES, INC.
A61K47/24A61F13/00063A61F13/02A61K8/0291A61K8/042A61K8/34A61K8/36A61K8/37A61K8/42A61K8/4953A61K8/553A61K8/86A61K9/0014A61K9/06A61K9/1075A61K31/137A61K31/167A61K31/196A61K31/245A61K31/454A61K31/7004A61K33/00A61K47/10A61K47/12A61K47/14A61K47/28A61Q7/00A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,052,152
App. No.
17/030,325
Granted
Jul 6, 2021
Kind
B2
Abstract

Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Claims (12)

1. A method for treating an individual to impede lactic acidosis, wherein the individual is administered a topical formulation for transdermal delivery of an active agent through the skin of a subject,

wherein said active agent comprises sodium bicarbonate,

wherein said formulation comprises a penetrant that provides a lecithin at 5%-15% w/w of said formulation and sodium bicarbonate at 20%-40% w/w of the formulation, wherein said formulation further comprises an isopropyl palmitate, benzyl alcohol at 0.5%-20% w/w of the formulation, propylene glycol at about 1%-5% w/w of the formulation, poloxamer 407 at 1%-15% w/w of the formulation.

2. The method of claim 1 , wherein the topical formulation further comprises sodium lauryl sulfate at 0.5%-2.5% w/w of the formulation.

3. The method of claim 1 , wherein the topical formulation further comprises one or more of ethanol and water.

4. The method of claim 1 , wherein the time for absorption was between 10-15 minutes following application.

5. The method of claim 1 , wherein the topical formulation increased athletic performance by up to 64%.

6. The method of claim 1 , wherein the topical formulation increases the time it takes for an individual to suffer from acidosis burn in the individual undertaking a form of muscle movement.

7. The method of claim 1 , wherein the topical formulation is applied to the individual prior to muscle exertion.

8. The method of claim 1 , wherein the topical formulation further comprises one or more of an electrolyte and readily metabolized nutrients.

9. The method of claim 1 , wherein the topical formulation further comprises one or more of beta-alanine, L-carnitine, adenosine triphosphate, dextrose, creatine monohydrate, beta-hydroxy-beta-methyl butyrate, branched chain amino acids, glutathione, sodium phosphate and caffeine.

10. The method of claim 1 , wherein the topical formulation is applied to the skin of the individual.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2021
From: SAND, BRUCE; BEAL, RYAN; BURNHAM, PHILLIPPE
To: DYVE BIOSCIENCES, INC.
Reel/Frame 057562/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2020
From: BURNHAM, PHILIPPE
To: AMPERSAND BIOPHARMACEUTICALS, INC.
Reel/Frame 054702/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2020
From: SAND, BRUCE J.
To: AMPERSAND BIOPHARMACEUTICALS, INC.
Reel/Frame 054702/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2020
From: BEAL, RYAN
To: DYVE BIOSCIENCES, INC.
Reel/Frame 054702/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2020
From: AMPERSAND BIOPHARMACEUTICALS, INC.
To: DYVE BIOSCIENCES, INC.
Reel/Frame 054702/0728 →
Continuity (22)
Continuation 16119178 · Aug 31, 2018
Continuation 15994927 · May 31, 2018
Continuation 14757703 · Dec 23, 2015
Continuation In Part PCTUS2014072239 · Dec 23, 2014
Provisional Application 62176416 · Feb 17, 2015
Provisional Application 62198605 · Jul 29, 2015
Provisional Application 62187756 · Jul 1, 2015
Provisional Application 62176418 · Feb 17, 2015
Provisional Application 62191952 · Jul 13, 2015
Provisional Application 62178232 · Apr 6, 2015
Provisional Application 62198599 · Jul 29, 2015
Provisional Application 62177814 · Mar 24, 2015
Provisional Application 62261167 · Nov 30, 2015
Provisional Application 62176438 · Feb 17, 2015
Provisional Application 62176417 · Feb 17, 2015
Provisional Application 62176414 · Feb 17, 2015
Provisional Application 62176415 · Feb 17, 2015
Provisional Application 62176419 · Feb 17, 2015
Provisional Application 62178192 · Apr 2, 2015
Provisional Application 62238012 · Oct 6, 2015
Provisional Application 62178193 · Apr 2, 2015
Related Publication 20210015925A1 · Jan 21, 2021
Cited By (1)
US 12,310,983